Table 1.
Study overview study 1 and study 2
| Study 1 | ||||||
|---|---|---|---|---|---|---|
| Study | Measures | Study designs | Compound | Dose (mg kg−1) | Strain | Number of rats |
| 1 Single administrations of different doses on separate days | MAP, HR and SV (CO and TPR) | Day 1: vehicle Following days: a different dose each day | Amiloride | 10 | SHR | 3 |
| Amlodipinec | 0.3, 1, 3, 10 | SHR | 2 | |||
| WKY | 2 | |||||
| Enalapril | 3, 10, 30 | SHR | 4d | |||
| Fasudil | 3, 10, 30 | SHR | 4 | |||
| HCTZa,c | 0.1, 0.3, 1, 3 | SHR | 2 | |||
| WKY | 2 | |||||
| HCTZb | 10, 30 | SHR | 4 | |||
| Prazosinc | 0.04, 0.2, 1, 5 | SHR | 2 | |||
| WKY | 1 | |||||
| Study 2 | |||
|---|---|---|---|
| Study | Measures | Study designs | Number of rats (SHR) |
| 2 Single, sequential or combined administration of atropine (10 mg kg−1) and/or propranolol (30 mg kg−1) | MAP, HR and SV (CO and TPR) | Vehicle followed by vehicle 3 h later | 2 |
| Atropine followed by propranolol 3 h later | 3d | ||
| Propranolol followed by atropine 3 h later | 3 | ||
| Combination of atropine and propranolol | 1 | ||
| Atropine followed by no dosing | 3d | ||
| Propranolol followed by no dosing | 3 | ||
1
First occasion.
2
Second occasion.
3
Data from SHR were previously used for the characterization of the CVS model (Snelder et al., 2013a).
4
Data from one rat were excluded for model development as this rat learned how to disconnect its flow cable and responded more strongly than all other rats resulting in a low MAP.